JPWO2020219941A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020219941A5 JPWO2020219941A5 JP2021562869A JP2021562869A JPWO2020219941A5 JP WO2020219941 A5 JPWO2020219941 A5 JP WO2020219941A5 JP 2021562869 A JP2021562869 A JP 2021562869A JP 2021562869 A JP2021562869 A JP 2021562869A JP WO2020219941 A5 JPWO2020219941 A5 JP WO2020219941A5
- Authority
- JP
- Japan
- Prior art keywords
- lipid
- moiety
- nanoparticle
- peg
- nanoparticles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000002632 lipids Chemical class 0.000 claims description 308
- 239000002105 nanoparticle Substances 0.000 claims description 175
- 239000002202 Polyethylene glycol Substances 0.000 claims description 59
- 229920001223 polyethylene glycol Polymers 0.000 claims description 59
- 125000000217 alkyl group Chemical group 0.000 claims description 40
- 239000002245 particle Substances 0.000 claims description 30
- 108020004707 nucleic acids Proteins 0.000 claims description 25
- 102000039446 nucleic acids Human genes 0.000 claims description 25
- 150000007523 nucleic acids Chemical class 0.000 claims description 25
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 24
- -1 cationic lipid Chemical class 0.000 claims description 20
- 230000002776 aggregation Effects 0.000 claims description 16
- 238000004220 aggregation Methods 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 15
- 235000012000 cholesterol Nutrition 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 108020004999 messenger RNA Proteins 0.000 claims description 11
- 150000003904 phospholipids Chemical class 0.000 claims description 10
- 108020004414 DNA Proteins 0.000 claims description 8
- 229930182558 Sterol Natural products 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 235000003702 sterols Nutrition 0.000 claims description 8
- 150000003432 sterols Chemical class 0.000 claims description 8
- 238000004873 anchoring Methods 0.000 claims description 7
- 108020004459 Small interfering RNA Proteins 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 229920001184 polypeptide Polymers 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 150000001841 cholesterols Chemical class 0.000 claims description 4
- 230000009395 genetic defect Effects 0.000 claims description 4
- 230000002018 overexpression Effects 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 125000003367 polycyclic group Chemical group 0.000 claims description 4
- 238000011321 prophylaxis Methods 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 2
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 2
- 125000006539 C12 alkyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 108091079001 CRISPR RNA Proteins 0.000 claims description 2
- 208000008425 Protein deficiency Diseases 0.000 claims description 2
- 238000010357 RNA editing Methods 0.000 claims description 2
- 230000026279 RNA modification Effects 0.000 claims description 2
- 230000004071 biological effect Effects 0.000 claims description 2
- 125000002091 cationic group Chemical group 0.000 claims description 2
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 230000007812 deficiency Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000014509 gene expression Effects 0.000 claims description 2
- 238000010362 genome editing Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 239000013612 plasmid Substances 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims 1
- 230000028993 immune response Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962839452P | 2019-04-26 | 2019-04-26 | |
| US62/839,452 | 2019-04-26 | ||
| US201962867098P | 2019-06-26 | 2019-06-26 | |
| US62/867,098 | 2019-06-26 | ||
| PCT/US2020/029907 WO2020219941A1 (en) | 2019-04-26 | 2020-04-24 | Lipid nanoparticles |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022530018A JP2022530018A (ja) | 2022-06-27 |
| JPWO2020219941A5 true JPWO2020219941A5 (https=) | 2023-04-27 |
| JP2022530018A5 JP2022530018A5 (https=) | 2023-04-27 |
Family
ID=72941858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021562869A Abandoned JP2022530018A (ja) | 2019-04-26 | 2020-04-24 | 脂質ナノ粒子 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220168222A1 (https=) |
| EP (1) | EP3959314A4 (https=) |
| JP (1) | JP2022530018A (https=) |
| CN (1) | CN114026233A (https=) |
| AU (1) | AU2020262437A1 (https=) |
| CA (1) | CA3137450A1 (https=) |
| MA (1) | MA55766A (https=) |
| WO (1) | WO2020219941A1 (https=) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021005462A (es) * | 2018-11-09 | 2021-08-24 | Arbutus Biopharma Corp | Lipidos cationicos que contienen silicio. |
| KR20220121246A (ko) | 2019-12-20 | 2022-08-31 | 큐어백 아게 | 핵산 전달용 신규한 지질 나노입자 |
| US12023376B1 (en) | 2020-04-17 | 2024-07-02 | Triad National Security, Llc | Conserved region T cell vaccines for coronavirus and methods of use |
| AU2021305214A1 (en) * | 2020-07-10 | 2023-02-23 | Genevant Sciences Gmbh | Lipid nanoparticles for delivering therapeutics to lungs |
| CN116234917A (zh) | 2020-07-27 | 2023-06-06 | 安杰瑞姆生物科学公司 | Dna分子组合物及其制备方法和使用方法 |
| CZ310613B6 (cs) | 2020-09-23 | 2026-01-28 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Lipidoidy pro transfekci nukleových kyselin a jejich použití |
| JP2023546175A (ja) | 2020-10-14 | 2023-11-01 | ジョージ・メイソン・リサーチ・ファウンデーション・インコーポレイテッド | 脂質ナノ粒子製造の方法及びそれに由来する組成物 |
| WO2022099003A1 (en) | 2020-11-06 | 2022-05-12 | Sanofi | Lipid nanoparticles for delivering mrna vaccines |
| IL303195A (en) | 2020-11-25 | 2023-07-01 | Akagera Medicines Inc | Lipid nanoparticles for delivery of nucleic acids and related methods of use |
| AU2021403156A1 (en) * | 2020-12-18 | 2023-07-13 | Genevant Sciences Gmbh | Peg lipids and lipid nanoparticles |
| WO2022198229A1 (en) * | 2021-03-17 | 2022-09-22 | Board Of Regents Of The University Of Nebraska | Lipid nanoparticle formulations and methods of use thereof |
| EP4323525A2 (en) | 2021-04-16 | 2024-02-21 | Genentech, Inc. | Optimized tlr7 ligands and uses thereof |
| CZ310443B6 (cs) | 2021-07-19 | 2025-06-25 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití |
| WO2023031392A2 (en) | 2021-09-03 | 2023-03-09 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine |
| US20250027107A1 (en) | 2021-10-18 | 2025-01-23 | Flagship Pioneering Innovations Vii, Llc | Dna compositions and related methods |
| KR20230061895A (ko) * | 2021-10-29 | 2023-05-09 | 주식회사 아이큐어비앤피 | 지질 나노입자 및 세포 투과성을 갖는 신규 펩타이드의 복합체 |
| WO2023218431A1 (en) | 2022-05-13 | 2023-11-16 | BioNTech SE | Rna compositions targeting hiv |
| CN117203186A (zh) * | 2022-05-13 | 2023-12-08 | 南方科技大学 | 一种含有二硫键的脂质化合物及其组合物 |
| AU2023275457A1 (en) | 2022-05-23 | 2024-11-28 | Astrazeneca Ab | Gene therapy compositions and methods of use thereof |
| KR20250021330A (ko) | 2022-05-25 | 2025-02-12 | 비온테크 에스이 | 원숭이두창 항원 전달을 위한 rna 조성물 및 관련 방법 |
| EP4531819A2 (en) | 2022-05-25 | 2025-04-09 | Akagera Medicines, Inc. | Lipid nanoparticles for delivery of nucleic acids and methods of use thereof |
| US20250375534A1 (en) | 2022-05-30 | 2025-12-11 | BioNTech SE | Complexes for delivery of nucleic acids |
| TWI858802B (zh) * | 2022-07-06 | 2024-10-11 | 南韓商綠十字股份有限公司 | 使用陽離子膽固醇用於核酸遞送的局部遞送的脂質納米顆粒 |
| EP4562154A2 (en) | 2022-07-29 | 2025-06-04 | Massachusetts Institute of Technology | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE SIGNAL REGULATORY PROTEIN ALPHA (SIRPalpha) GENE |
| WO2024037577A1 (en) * | 2022-08-18 | 2024-02-22 | Suzhou Abogen Biosciences Co., Ltd. | Composition of lipid nanoparticles |
| WO2024057237A1 (en) | 2022-09-16 | 2024-03-21 | Pfizer Inc. | Lipid nanoparticles |
| EP4342460A1 (en) | 2022-09-21 | 2024-03-27 | NovoArc GmbH | Lipid nanoparticle with nucleic acid cargo |
| WO2024131810A1 (en) * | 2022-12-21 | 2024-06-27 | Suzhou Abogen Biosciences Co., Ltd. | Lipid nanoparticles comprising sterol-modified phospholipids |
| WO2024141955A1 (en) | 2022-12-28 | 2024-07-04 | BioNTech SE | Rna compositions targeting hiv |
| EP4410316A1 (en) * | 2023-02-01 | 2024-08-07 | 4basebio UK Ltd | Nanoparticles for delivery of nucleic acid cargos |
| AU2024217077A1 (en) * | 2023-02-06 | 2025-09-18 | University Of Tennessee Research Foundation | Multi-functional lipid nanoparticles and uses thereof |
| WO2024205499A1 (en) * | 2023-03-27 | 2024-10-03 | Agency For Science, Technology And Research | A compound for preparing lipid nanoparticles encapsulating an agent, nanoparticle composition comprising said compound and related methods thereof |
| WO2024259158A2 (en) * | 2023-06-13 | 2024-12-19 | Cornell University | Lipid nanoparticles for peptide delivery and methods of making and using the same |
| CN121866336A (zh) | 2023-08-03 | 2026-04-14 | 百欧恩泰欧洲股份公司 | 靶向hiv的rna组合物 |
| WO2025027579A2 (en) | 2023-08-03 | 2025-02-06 | BioNTech SE | Rna compositions targeting hiv |
| IL326647A (en) | 2023-09-01 | 2026-04-01 | Novoarc Gmbh | Lipid nanoparticles with a nucleic acid charge and an ionizable lipid |
| WO2025124711A1 (en) | 2023-12-13 | 2025-06-19 | BioNTech SE | Glycolipid compositions |
| WO2025219570A1 (en) | 2024-04-17 | 2025-10-23 | Johannes Kepler Universität Linz | Composition for inhibiting protein translocation and methods using the same |
| WO2025242657A1 (en) | 2024-05-21 | 2025-11-27 | Shape Biopharmaceuticals Ag | Lipopeptide building blocks and aggregates |
| GB202408360D0 (en) | 2024-06-11 | 2024-07-24 | Cancer Research Tech Ltd | Tumour sensitisation |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20220652T1 (hr) * | 2015-12-10 | 2022-06-24 | Modernatx, Inc. | Pripravci i postupci unosa terapijskih sredstava |
| CN109563511A (zh) * | 2016-06-30 | 2019-04-02 | 阿布特斯生物制药公司 | 用于递送信使rna的组合物和方法 |
-
2020
- 2020-04-24 AU AU2020262437A patent/AU2020262437A1/en not_active Abandoned
- 2020-04-24 CN CN202080046391.4A patent/CN114026233A/zh active Pending
- 2020-04-24 WO PCT/US2020/029907 patent/WO2020219941A1/en not_active Ceased
- 2020-04-24 MA MA055766A patent/MA55766A/fr unknown
- 2020-04-24 JP JP2021562869A patent/JP2022530018A/ja not_active Abandoned
- 2020-04-24 CA CA3137450A patent/CA3137450A1/en active Pending
- 2020-04-24 US US17/605,698 patent/US20220168222A1/en not_active Abandoned
- 2020-04-24 EP EP20795521.2A patent/EP3959314A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020219941A5 (https=) | ||
| JP7066632B2 (ja) | 親油性抗炎症剤を含む脂質ナノ粒子およびその使用方法 | |
| CN107208095B (zh) | 用于使乙型肝炎病毒基因表达沉默的组合物和方法 | |
| US10155945B2 (en) | Method of producing lipid nanoparticles for drug delivery | |
| US20130122096A1 (en) | Compositions for drug delivery and methods of manufacturing and using same | |
| US20070293449A1 (en) | Compositions and methods for delivery of double-stranded rna | |
| JPWO2020097540A5 (https=) | ||
| JP2017536092A5 (https=) | ||
| TW201323020A (zh) | 用於藥物傳遞之脂質奈米粒子的製造方法 | |
| CN104736181A (zh) | 包含靶向聚氨基酸与脂肪酸之缀合物的药物递送载剂 | |
| KR20140065017A (ko) | 약물 담체 | |
| JP2017500865A (ja) | レプチンｍＲＮＡの組成物および製剤 | |
| JPWO2023044343A5 (https=) | ||
| JP7821776B2 (ja) | 効率的な核酸送達のための担体 | |
| TW202539707A (zh) | 用於治療ｂ型肝炎之治療組成物及方法 | |
| JP2024500158A (ja) | １，２－ジオレオイル－３－トリメチルアンモニウム－プロパン（ｄｏｔａｐ）脂質ナノ粒子による組織特異的核酸送達 | |
| JP2023508882A (ja) | メッセンジャーｒｎａの直腸送達 | |
| JP2022087209A (ja) | Ｂ型肝炎を治療するための治療用組成物及び方法 | |
| JP2020512293A (ja) | インフュージョンリアクションを改善するための方法 | |
| JP2024516152A (ja) | 混合カチオン性脂質粒子による組織特異的核酸送達 | |
| TW201919653A (zh) | 用於治療ｂ型肝炎之治療組合物及方法 | |
| JP5382682B2 (ja) | 薬物送達複合体 | |
| JPWO2023044333A5 (https=) | ||
| CN116615233A (zh) | 用于使生物分子在受试者中表达的系统和方法 | |
| KR20170086638A (ko) | 약학 조성물, 이의 제조 및 용도 |